Home/Filings/4/0001019687-10-000261
4//SEC Filing

BIOASIA INVESTMENTS IV LLC 4

Accession 0001019687-10-000261

CIK 0001282393other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 8:33 PM ET

Size

14.7 KB

Accession

0001019687-10-000261

Insider Transaction Report

Form 4
Period: 2010-01-19
Transactions
  • Sale

    Common Stock

    2010-01-19$5.51/sh198,487$1,094,0801,209,057 total(indirect: By Biotechnology Development Fund IV, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh3,669$20,22422,347 total(indirect: By Biotechnology Development Fund IV Affiliates, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh58,182$320,705354,406 total(indirect: By BioAsia Crossover Fund, L.P.)
Transactions
  • Sale

    Common Stock

    2010-01-19$5.51/sh58,182$320,705354,406 total(indirect: By BioAsia Crossover Fund, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh198,487$1,094,0801,209,057 total(indirect: By Biotechnology Development Fund IV, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh3,669$20,22422,347 total(indirect: By Biotechnology Development Fund IV Affiliates, L.P.)
Transactions
  • Sale

    Common Stock

    2010-01-19$5.51/sh198,487$1,094,0801,209,057 total(indirect: By Biotechnology Development Fund IV, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh58,182$320,705354,406 total(indirect: By BioAsia Crossover Fund, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh3,669$20,22422,347 total(indirect: By Biotechnology Development Fund IV Affiliates, L.P.)
Transactions
  • Sale

    Common Stock

    2010-01-19$5.51/sh58,182$320,705354,406 total(indirect: By BioAsia Crossover Fund, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh3,669$20,22422,347 total(indirect: By Biotechnology Development Fund IV Affiliates, L.P.)
  • Sale

    Common Stock

    2010-01-19$5.51/sh198,487$1,094,0801,209,057 total(indirect: By Biotechnology Development Fund IV, L.P.)
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.53. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F2]The reported securities are owned directly by Biotechnology Development Fund IV Affiliates, L.P. and indirectly by BioAsia Investments IV, LLC, as general partner of Biotechnology Development Fund IV Affiliates, L.P. BioAsia Investments IV, LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.
  • [F3]The reported securities are owned directly by Biotechnology Development Fund IV, L.P. and indirectly by BioAsia Investments IV, LLC, as general partner of Biotechnology Development Fund IV, L.P. BioAsia Investments IV, LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.
  • [F4]The reported securities are owned directly by BioAsia Crossover Fund, L.P. and indirectly by BioAsia Investments IV, LLC, as general partner of BioAsia Crossover Fund, L.P. BioAsia Investments IV, LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

Issuer

BIOFORM MEDICAL INC

CIK 0001282393

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001261786

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 8:33 PM ET
Size
14.7 KB